18 May 2013
Keywords: novartis, prexige, withdrawn, uk, german, austrian, regulators
Article | 26 November 2007
Health regulators in the UK and Germany have suspended the marketing and sale of Novartis' Prexige (lumiracoxib), a COX-2 inhibitor ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
26 November 2007
17 May 2013
© 2013 thepharmaletter.com